Patients with atypical Alzheimer disease frequently fail to meet the clinical criteria required to receive targeted anti-amyloid therapies.

Treatment with intravenous inebilizumab is associated with a significantly decreased risk for exacerbations in adults with generalized myasthenia gravis.

Time-restricted eating may be a safe and reasonable method for improving disease markers in people with Huntington disease.

Pediatric patients receiving GLP-1 receptor agonist treatment appear to have higher rates of nutritional deficiency.

Multiple-component and multifactorial interventions do not meaningfully improve fall rates among older people compared with usual care.

An FDA panel supports Galleri, a blood test designed to detect multiple cancer types, despite some concern that the test is not reliable.

Assessment tools significantly influence the reported global prevalence of cognitive frailty among older adult populations.

The FDA granted Orphan Drug designation to Qivigy (immune globulin intravenous) for stiff person syndrome, an ultra-rare neurological disorder.

Calculating brain-predicted age difference using MRI data helps identify patients with subjective cognitive decline at higher risk for dementia.

Most hospital readmissions following a subdural hematoma are driven by nonsurgical causes such as infections and cardiovascular conditions.

A majority of middle-aged adults in the US report an interest in receiving preventive dementia vaccination if available.

Patient-centered surgical outcomes were not negatively affected by substantially reduced intraoperative crystalloid fluid administration.